BioTuesdays

Tag - CTXR

Markets

EF Hutton starts Citius Pharmaceuticals at buy; PT $6

EF Hutton launched coverage of Citius Pharmaceuticals (NASDAQ:CTXR) a “buy” rating and $6 target price. The stock closed at $0.7340 on July 12. Citius is a pharmaceutical/biotechnology company with two late-stage assets...

July 15, 2024
Citius Logo
Markets

Maxim starts Citius Pharma at buy; PT $4

Maxim Group launched coverage of Citius Pharmaceuticals (NASDAQ:CTXR) with a “buy” rating and $4 price target. The stock closed at $1.62 on Nov. 29. Citius is a late-stage company with two “de-risked” Phase 3 assets:...

November 30, 2021
Citius Logo
Markets

HCW starts Citius Pharma at buy; PT $11

H.C. Wainwright initiated coverage of Citius Pharmaceuticals (NASDAQ:CTXR) with a “buy” rating and price target of $11. The stock finished at $2.40 on May 22. The company’s antibiotic lock therapy drug combination, Mino...

May 23, 2018